Autonomous technology, development of smart cities dominate CES
CSX revenue misses estimates on disruptions from turnaround plan
Harrison, a veteran railroader cherished by investors for leading turnarounds of Canadian railroads, died in December, just eight months into his restructuring campaign at CSX that includes a strategy to run trains on tight schedules rather than on customer needs. Investors have been searching for clarity on how new CEO Jim Foote will handle the turnaround plan that also includes deep job cuts and rail yard closures and has triggered persistent service disruptions, customer complaints and federal scrutiny. "I see no reason to believe we can't deliver the results that Hunter thought we could," Foote said on a post-earnings call.
What Happened in the Stock Market Today
On a day stocks bounced up and down, shares of Energizer Holdings rose on acquisition news, and Merck reported positive results in a lung cancer trial.
VIX May Have Finally Found Its Floor, Macro Risk Advisors Say
Volatility can't stay this low forever -- or so investors have been saying for what feels like forever. They may have finally found their moment.
Lindsey Graham Sends Trump a Message: We Need ‘a Reliable Partner in the White House’
Sen. Lindsey Graham (R-SC), one of the senators behind the bipartisan immigration deal that the president rejected last week, said Tuesday that someone on the White House staff “gave him really bad advice” ahead of that heated meeting on Thursday. White House Chief of Staff John Kelly and senior adviser Stephen Miller reportedly brought in other members of Congress to push back against the proposed deal. “I don't think the president was well-served by his staff,” Graham told reporters Tuesday.
Goldman Sachs, Bank of America, and the Fed — What you need to know in markets on Wednesday
Bank of America and Goldman Sachs will report earnings on Wednesday during a pivotal week for the banking sector.
Celgene in talks to buy Juno Therapeutics – WSJ
Shares of Juno, which has a market value of $5.57 billion, were up 42 percent at $64.59 in extended trading. Chimeric antigen receptor T-cell therapy, or CAR T, harnesses the body's own immune cells to recognize and attack malignant cells.